TY - JOUR
T1 - High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease
AU - Kastrup, Jens
AU - Johansen, Julia S
AU - Winkel, Per
AU - Hansen, Jørgen Fischer
AU - Hildebrandt, Per
AU - Jensen, Gorm Boje
AU - Jespersen, Christian M
AU - Kjøller, Erik
AU - Kolmos, Hans Jørn
AU - Lind, Inga
AU - Nielsen, Henrik
AU - Gluud, Christian
AU - CLARICOR Trial Group
AU - Kastrup, Jens
AU - Johansen, Julia S
AU - Winkel, Per
AU - Hansen, Jørgen Fischer
AU - Hildebrandt, Per
AU - Jensen, Gorm Boje
AU - Jespersen, Christian M
AU - Kjøller, Erik
AU - Kolmos, Hans Jørn
AU - Lind, Inga
AU - Nielsen, Henrik
AU - Gluud, Christian
AU - CLARICOR Trial Group, null
N1 - Keywords: Acute Coronary Syndrome; Aged; Biological Markers; Cause of Death; Coronary Angiography; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Lectins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prognosis; Survival Analysis
PY - 2009
Y1 - 2009
N2 - AIMS: Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). METHODS AND RESULTS: During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). CONCLUSION: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.
AB - AIMS: Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concentration predicts coronary events and death of patients with stable coronary artery disease (CAD). METHODS AND RESULTS: During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as cardiovascular death). Serum YKL-40 transformed as Y=log[max(82, serum YKL-40/microg/L)] was significantly associated with cardiovascular death [hazard ratio (HR) = 1.88, 95% confidence interval (CI) = 1.54-2.31, P < 0.001], all-cause mortality (HR = 2.01, 95% CI = 1.75-2.31, P < 0.001), and MI (HR = 1.38, 95% CI = 1.13-1.68, P = 0.002). Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality (P < 0.001) and cardiovascular mortality (P = 0.001), but not MI (P = 0.25). CONCLUSION: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.
U2 - 10.1093/eurheartj/ehp049
DO - 10.1093/eurheartj/ehp049
M3 - Journal article
C2 - 19270316
SN - 0195-668X
VL - 30
SP - 1066
EP - 1072
JO - European Heart Journal
JF - European Heart Journal
IS - 9
ER -
